What Dx Biosamples does

Dx Biosamples is a human biospecimen contract procurement organization headquartered in San Diego, California, founded in 2010. The company procures custom-collected human specimens — including tissues, blood, and biofluids — paired with comprehensive clinical data for pharmaceutical, biotechnology, and diagnostic sponsors across oncology, autoimmune, neurology, kidney, pulmonology, infectious diseases, and OB/GYN.

The offering is built on a nationwide network of clinical collection sites operating under IRB-approved protocols and HIPAA, GCP, and ICH compliance frameworks. Specimens are bundled with annotated clinical records, positioning the company as a curated procurement partner rather than a tissue broker or biobank; this clinical-data layer is the principal technical feature distinguishing it from catalog resellers.

The business operates on a project-based, quote-driven pricing model sold directly to enterprise clients — visible counterparties include Abbott, AstraZeneca, Bio-Rad, Boehringer Ingelheim, Epigenomics, Genentech, Genomic Health, Illumina, MedImmune, Roche, and Sanofi. The firm is privately held with a 1-10 employee headcount, consistent with a small, founder-led services operation rather than a scaled platform.

Name

Dx Biosamples

Legal name

Dx Biosamples, LLC

Website

https://dxbiosamples.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Dx Biosamples is a San Diego-based human biospecimen procurement firm founded in 2010, supplying custom tissue, blood, and biofluid samples with clinical data to pharmaceutical, biotechnology, and diagnostic companies across multiple disease areas.

Ownership category

akta.pro rank

Product category

Biospecimen Procurement Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Human biospecimen procurement
• Clinical specimen collection
• Biospecimen supply services
• Human tissue specimens
• Biorepository procurement

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Technology or R&D

Revenue model

1. Biospecimen Procurement Services: Custom collection and procurement of human biospecimens (tissues, blood, biofluids) with associated clinical data. Services include prospective collection, longitudinal study support, and provision of banked/remnant samples. Revenue generated through project-based contracts with pharmaceutical and biotech clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Dx Biosamples is a contract procurement organization that sources and delivers human biospecimens — including fresh, frozen, and FFPE tissues, blood, serum, plasma, urine, and other biofluids — to pharmaceutical, biotechnology, and diagnostic companies. Specimens are collected under IRB-approved protocols from a nationwide network of clinical sites and supplied with comprehensive, de-identified clinical data and pathology reports covering major disease states such as Oncology, Neurology, Autoimmune, Kidney, Pulmonology, Infectious Diseases, and OB/GYN.

Product overview

Dx Biosamples is a human biospecimen contract procurement organization offering a unified portfolio of specimen procurement services. The core offering is Biospecimen Procurement Services, which provides fresh, frozen, and FFPE specimens (tissues, blood, serum, plasma, urine, and other biofluids) with comprehensive clinical data. This is supported by Custom Services that handle project coordination, IRB submissions, ethical specimen collection protocols, clinical data development, and quality assurance. Specimens are organized by Disease State categories spanning Oncology, Neurology, Infectious Diseases, Autoimmune/Rheumatology, Pulmonology, Kidney Diseases, and OB/GYN. Both prospective specimen collection (with longitudinal study support) and banked/remnant sample options are available.

Differentiator

Problem solved

Functional benefit

Products and services

• Biospecimen Procurement Services

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• BioIVT: Largest independent provider of human biospecimens and biorepository services globally. Directly comparable because BioIVT competes for the same pharmaceutical, biotech, and diagnostic buyers with prospective collection, banked samples, and IRB-compliant clinical data offerings.
• Discovery Life Sciences: Major human biospecimen procurement and bioservices company. Directly comparable as it serves pharma, biotech, and diagnostic clients with fresh and banked specimens across oncology, autoimmune, neurology, and other disease states.
• iSpecimen: Technology-enabled marketplace for human biospecimens. Directly comparable as it connects researchers with a network of clinical sites and biospecimen suppliers, competing for the same enterprise buyer RFPs as Dx Biosamples.
• Azenta Life Sciences (Brooks Life Sciences): Provider of sample management, biorepository, and biospecimen services to life science customers. Directly comparable in biorepository and sample logistics, particularly for trial support and large-scale pharma specimen programs.
• Cureline: Human biospecimen CRO focused on prospective collection of diseased and normal tissues with clinical data. Directly comparable due to similar service model and target customer base in pharma and diagnostic R&D.
• Indivumed: Specialty biospecimen provider emphasizing oncology tissue with extensive clinical annotation. Directly comparable as it serves pharma and diagnostic developers with high-quality, well-characterized cancer specimens.
• Sanguine Biosciences: Direct-to-patient biospecimen collection service for pharma and biotech research. Directly comparable in prospective specimen collection, IRB-compliant protocols, and disease-state coverage for translational research.

Broad incumbents

• Caprion Biosciences: Specialty biomarker and immune-monitoring lab serving pharma and biotech. Comparable as an adjacent buyer and sometimes supplier of clinical specimens, though its core offering is specialized assay services rather than specimen procurement.
• SeraCare Life Sciences (now part of LGC Clinical Diagnostics): Provider of biological reference materials and diagnostic reagents. Comparable as a broader life-science tools player serving similar diagnostic and pharma customers with biological materials, though positioned more as a manufacturer than a procurement intermediary.

Emerging players

• Precision Biospecimens: Smaller specialty biospecimen provider focused on cancer and rare-disease specimens. Comparable as a niche competitor pursuing similar enterprise buyers with prospective and banked tissue collections.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dx-biosamples-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dx Biosamples